Dr Jordyn Stuart

A16 - Badham Building
The University of Sydney

Selected publications

Download citations: PDF RTF Endnote

Journals

  • Suraev, A., Lintzeris, N., Stuart, J., Kevin, R., Blackburn, R., Richards, E., Arnold, J., Ireland, C., Todd, L., Allsop, D., McGregor, I. (2018). Author Correction: Composition and Use of Cannabis Extracts for Childhood Epilepsy in the Australian Community. Scientific Reports, 8(1), 1-1. [More Information]
  • Suraev, A., Lintzeris, N., Stuart, J., Kevin, R., Blackburn, R., Richards, E., Arnold, J., Ireland, C., Todd, L., Allsop, D., McGregor, I. (2018). Composition and Use of Cannabis Extracts for Childhood Epilepsy in the Australian Community. Scientific Reports, 8(1), 28127. [More Information]
  • Russell, J., Maguire, S., Hunt, G., Kesby, A., Suraev, A., Stuart, J., Booth, J., McGregor, I. (2018). Intranasal oxytocin in the treatment of anorexia nervosa: Randomized controlled trial during re-feeding. Psychoneuroendocrinology, 87, 83-92. [More Information]
  • Banister, S., Olson, A., Winchester, M., Stuart, J., Edington, A., Kevin, R., Longworth, M., Herrera, M., Connor, M., McGregor, I., Kassiou, M., et al (2018). The chemistry and pharmacology of synthetic cannabinoid SDB-006 and its regioisomeric fluorinated and methoxylated analogs. Drug Testing and Analysis, 10(7), 1099-1109. [More Information]
  • Kevin, R., Wood, K., Stuart, J., Mitchell, A., Moir, M., Banister, S., Kassiou, M., McGregor, I. (2017). Acute and residual effects in adolescent rats resulting rrom exposure to the novel synthetic cannabinoids AB-PINACA and AB-FUBINACA. Journal of Psychopharmacology, 31(6), 757-769. [More Information]
  • Soethoudt, M., Grether, U., Fingerle, J., Grim, T., Fezza, F., de Petrocellis, L., Ullmer, C., Rothenhausler, B., Perret, C., van Gils, N., et al (2017). Cannabinoid CB2 receptor ligand profiling reveals biased signalling and off-target activity. Nature Communications, 8(13958), 1-14. [More Information]
  • Clarke, D., Stuart, J., McGregor, I., Arnold, J. (2017). Endocannabinoid dysregulation in cognitive and stress-related brain regions in the Nrg1 mouse model of schizophrenia. Progress in Neuro-Psychopharmacology & Biological Psychiatry, 72, 9-15. [More Information]
  • Leishman, E., Kunkler, P., Manchanda, M., Sangani, K., Stuart, J., Oxford, G., Hurley, J., Bradshaw, H. (2017). Environmental toxin acrolein alters levels of endogenous lipids, including TRP agonists: A potential mechanism for headache driven by TRPA1 activation. Neurobiology of Pain, 1, 28-36. [More Information]
  • Brzozowska, N., Li, K., Wang, X., Booth, J., Stuart, J., McGregor, I., Arnold, J. (2016). ABC transporters P-gp and Bcrp do not limit the brain uptake of the novel antipsychotic and anticonvulsant drug cannabidiol in mice. PeerJ, 4(5), 1-17. [More Information]
  • Redmond, W., Cawston, E., Grimsey, N., Stuart, J., Edington, A., Glass, M., Connor, M. (2016). Identification of N-arachidonoyl dopamine as a highly biased ligand at cannabinoid CB1 receptors. British Journal of Pharmacology, 173, 115-127.
  • Banister, S., Longworth, M., Kevin, R., Sachdev, S., Santiago, M., Stuart, J., Mack, J., Glass, M., McGregor, I., Connor, M., Kassiou, M. (2016). Pharmacology of Valinate and tert-Leucinate Synthetic Cannabinoids 5F-AMBICA, 5F-AMB, 5F-ADB, AMB-FUBINACA, MDMB-FUBINACA, MDMB-CHMICA, and Their Analogues. ACS Chemical Neuroscience, 7(9), 1241-1254. [More Information]
  • Banister, S., Moir, M., Stuart, J., Kevin, R., Wood, K., Longworth, M., Wilkinson, S., Beinat, C., Buchanan, A., Glass, M., McGregor, I., Kassiou, M., et al (2015). Pharmacology of indole and indazole synthetic cannabinoid designer drugs AB-FUBINACA, ADB-FUBINACA, AB-PINACA, ADB-PINACA, 5F-AB-PINACA, 5F-ADB-PINACA, ADBICA, and 5F-ADBICA. ACS Chemical Neuroscience, 6(9), 1546-1559. [More Information]

2018

  • Suraev, A., Lintzeris, N., Stuart, J., Kevin, R., Blackburn, R., Richards, E., Arnold, J., Ireland, C., Todd, L., Allsop, D., McGregor, I. (2018). Author Correction: Composition and Use of Cannabis Extracts for Childhood Epilepsy in the Australian Community. Scientific Reports, 8(1), 1-1. [More Information]
  • Suraev, A., Lintzeris, N., Stuart, J., Kevin, R., Blackburn, R., Richards, E., Arnold, J., Ireland, C., Todd, L., Allsop, D., McGregor, I. (2018). Composition and Use of Cannabis Extracts for Childhood Epilepsy in the Australian Community. Scientific Reports, 8(1), 28127. [More Information]
  • Russell, J., Maguire, S., Hunt, G., Kesby, A., Suraev, A., Stuart, J., Booth, J., McGregor, I. (2018). Intranasal oxytocin in the treatment of anorexia nervosa: Randomized controlled trial during re-feeding. Psychoneuroendocrinology, 87, 83-92. [More Information]
  • Banister, S., Olson, A., Winchester, M., Stuart, J., Edington, A., Kevin, R., Longworth, M., Herrera, M., Connor, M., McGregor, I., Kassiou, M., et al (2018). The chemistry and pharmacology of synthetic cannabinoid SDB-006 and its regioisomeric fluorinated and methoxylated analogs. Drug Testing and Analysis, 10(7), 1099-1109. [More Information]

2017

  • Kevin, R., Wood, K., Stuart, J., Mitchell, A., Moir, M., Banister, S., Kassiou, M., McGregor, I. (2017). Acute and residual effects in adolescent rats resulting rrom exposure to the novel synthetic cannabinoids AB-PINACA and AB-FUBINACA. Journal of Psychopharmacology, 31(6), 757-769. [More Information]
  • Soethoudt, M., Grether, U., Fingerle, J., Grim, T., Fezza, F., de Petrocellis, L., Ullmer, C., Rothenhausler, B., Perret, C., van Gils, N., et al (2017). Cannabinoid CB2 receptor ligand profiling reveals biased signalling and off-target activity. Nature Communications, 8(13958), 1-14. [More Information]
  • Clarke, D., Stuart, J., McGregor, I., Arnold, J. (2017). Endocannabinoid dysregulation in cognitive and stress-related brain regions in the Nrg1 mouse model of schizophrenia. Progress in Neuro-Psychopharmacology & Biological Psychiatry, 72, 9-15. [More Information]
  • Leishman, E., Kunkler, P., Manchanda, M., Sangani, K., Stuart, J., Oxford, G., Hurley, J., Bradshaw, H. (2017). Environmental toxin acrolein alters levels of endogenous lipids, including TRP agonists: A potential mechanism for headache driven by TRPA1 activation. Neurobiology of Pain, 1, 28-36. [More Information]

2016

  • Brzozowska, N., Li, K., Wang, X., Booth, J., Stuart, J., McGregor, I., Arnold, J. (2016). ABC transporters P-gp and Bcrp do not limit the brain uptake of the novel antipsychotic and anticonvulsant drug cannabidiol in mice. PeerJ, 4(5), 1-17. [More Information]
  • Redmond, W., Cawston, E., Grimsey, N., Stuart, J., Edington, A., Glass, M., Connor, M. (2016). Identification of N-arachidonoyl dopamine as a highly biased ligand at cannabinoid CB1 receptors. British Journal of Pharmacology, 173, 115-127.
  • Banister, S., Longworth, M., Kevin, R., Sachdev, S., Santiago, M., Stuart, J., Mack, J., Glass, M., McGregor, I., Connor, M., Kassiou, M. (2016). Pharmacology of Valinate and tert-Leucinate Synthetic Cannabinoids 5F-AMBICA, 5F-AMB, 5F-ADB, AMB-FUBINACA, MDMB-FUBINACA, MDMB-CHMICA, and Their Analogues. ACS Chemical Neuroscience, 7(9), 1241-1254. [More Information]

2015

  • Banister, S., Moir, M., Stuart, J., Kevin, R., Wood, K., Longworth, M., Wilkinson, S., Beinat, C., Buchanan, A., Glass, M., McGregor, I., Kassiou, M., et al (2015). Pharmacology of indole and indazole synthetic cannabinoid designer drugs AB-FUBINACA, ADB-FUBINACA, AB-PINACA, ADB-PINACA, 5F-AB-PINACA, 5F-ADB-PINACA, ADBICA, and 5F-ADBICA. ACS Chemical Neuroscience, 6(9), 1546-1559. [More Information]

To update your profile click here. For support on your academic profile contact .